Torrey Pines Investment

07/28/2022

Interesting comparison of the currently approved antivirals for COVID-19 by Viriom Inc. MDPI

A complete response to the challenge of COVID-19 requires diagnosis, prevention, and treatment strategies. Until recently, the treatment arm has included largely ineffective, often unproven medications with minimal impact on disease outcomes. The earlier experimental therapies are now giving way to....

09/14/2021

Announcing new start-up investments aimed to bring proprietary small molecule products to the clinic targeting cancer! Together with OrbiMed we continue to build a robust innovative pipeline focused on breakthrough drug targets, bringing the total funding for 9 companies in the Loch platform to over $68.5 million. Learn more at https://lnkd.in/gwB-DWQa

04/29/2021

i2020 just announced additional financing for breakthrough Cancer-, Inflammation- and Neurology-focused therapeutics together with OrbiMed! Learn more
https://lnkd.in/dzXRaJP

03/09/2021

Great results for Viriom Inc and Chromis Therapeutics - Avifavir has shown early and statistically significant differentiation compared to Standard of Supportive Care for Covid-19 patients, with a 33% faster virological response, 20% shorter time to normalized clinical symptoms; and 31% lower mortality rate.
http://chromisthera.com/about-4/avifavir/

Happy to announce that we have presented results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021. https://www.prnewswire.com/news-releases/viriom-and-chromis-publish-results-of-a-multi-center-open-label-post-marketing-clinical-study-in-940-covid-19-patients-confirming-efficacy-of-avifavir-at-croi2021-301243948.html?tc=eml_cleartime

Avifavir, one of the leading directly acting antiviral drugs against COVID-19 globally, has been delivered to over 1,000,000 patients in 17 countries in 2020 and we are excited about the continuous adoption of an early treatment with this effective, safe and tolerable direct antiviral by healthcare systems globally. Learn more at http://chromisthera.com/about-4/avifavir/

07/30/2020

Excited to announce that i2020 Accelerator together with OrbiMed will be investing $28.5M into innovative oncology discovery programs of 4 companies! Learn more https://seekingalpha.com/pr/17951693-i2020-accelerator-of-torrey-pines-investment-in-breakthrough-cancer-programs-together-orbimed

05/04/2020

Viriom Inc is initiating a Phase 2a study investigating the efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients. The results of the Phase 1 study have been presented at CROI 2020 in Boston. Learn more https://www.marketwatch.com/press-release/viriom-announces-initiation-of-phase-2-study-investigating-efficacy-of-intramuscular-long-acting-injectable-nanoformulation-of-vm1500a-in-hiv-infected-patients-2020-05-04

Encouraged by the results of the Phase 1 study of safety and pharmacokinetics, we are now exploring the potential of delivering therapeutic doses of VM1500A over 4 and 8-week periods! Confirmed slow release with sustained therapeutic concentration levels allow us to capture the potential of VM1500A for HIV-1 long acting therapy and pre-exposure prophylaxis (PrEP).
https://www.marketwatch.com/press-release/viriom-announces-initiation-of-phase-2-study-investigating-efficacy-of-intramuscular-long-acting-injectable-nanoformulation-of-vm1500a-in-hiv-infected-patients-2020-05-04

04/08/2020

Indeed an exciting study of Viriom Inc investigational new drug against COVID-19, looking forward to the results!

Excited to be starting Phase 2 clinical study of elsulfavirine for treatment of COVID-19! The new clinical study expands the ongoing research into elsulfavirine, which includes confirmation of elsulfavirine antiviral activity against COVID-19 infection by the State Key Laboratory of Diagnosis and Treatment of Infectious Diseases, Zhejiang University in China.
https://seekingalpha.com/pr/17831415-viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covidminus-19

03/24/2020

Viriom Inc is working with Chinese Center for Disease Control and Prevention and select health authorities in the US as well as globally to determine the antiviral activity of Elpida and several other drug candidates against COVID-19. https://seekingalpha.com/pr/17816949-viriom-donates-elpida-to-chinese-and-russian-governments-for-experimental-use-against

02/17/2020

Come out and meet Viriom Inc at CROI 2020! Email Iain Dukes at idukes@viriom.com to set up a meeting.

Come meet us at CROI 2020 in Boston on March 8-11! Professor Robert Murphy will be presenting the results of Phase I study on safety and pharmacology of the long acting injectable nanoformulation of our novel NNRTi for treatment of HIV-1 infection. Looking forward to seeing you there! https://lnkd.in/gr_85Jm

12/03/2019

Excited to be launching Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy, supported by preclinical services of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. https://www.prnewswire.com/news-releases/viriom-launches-reproductive-toxicity-studies-for-elpida-elsulfavirine-once-weekly-oral-formulation-300967876.html

10/22/2019

Excited about our new collaboration with University of Turku, ChemDiv and i2020 Accelerator to help advance the development of novel neuroprotectants and non-addictive pain treatments with high specificity. Learn more about the cutting-edge research program at UTU here https://www.morningstar.com/news/pr-newswire/20191021la09446/i2020-accelerator-invests-in-developing-novel-highly-specific-approaches-to-treatment-of-neurodegenerative-diseases-based-on-previously-unrecognized-protein-protein-interactions

09/04/2019

Congratulations to Viriom Inc for winning a grant award to establish its affiliate in Mainland China!

Having opened a representative office in Beijing in 2017, we are now establishing an affiliate in Hong Kong and have just won a grant award to establish an affiliate in Mainland China! https://www.thestreet.com/press-releases/viriom-wins-grant-award-to-establish-affiliate-in-mainland-china-15076359

08/16/2019

Meet i2020 Accelerator at the LSX Nordic Congress on 28-29 August 2019! They have plenty to share when it comes to effective management of investment, business planning and partnering opportunities.

07/25/2019

Happy to announce that we have achieved a milestone with SnapBio, a member of our i2020 Accelerator, in developing several promising small molecule lead candidates with an outstanding selectivity profile for treatment of Hepatocellular carcinoma (HCC) and Hepatoblastoma together with ChemDiv. Learn more https://www.prnewswire.com/news-releases/snap-bio-and-i2020-accelerator-torrey-pines-investment-reach-lead-compounds-milestone-for-pediatric-oncology-and-advanced-liver-cancer-programs-300890754.html

12/21/2018

A once weekly oral formulation of HIV treatment - great potential, waiting to see the results of the trials in March 2019!

Excited to report results from Phase 1b clinical trial of once weekly dosing of oral elsulfavirine (Elpida®, VM1500), a potent long acting nonnucleoside reverse transcriptase inhibitor (NNRTI) in HIV-uninfected volunteers in March 2019!

12/20/2018

A very promising trial - less frequent dosing could facilitate patients' adherence to HIV treatment and improve treatment outcomes.

Happy to announce that we have started Phase 1 trials of
a potential once monthly or once quarterly injectable HIV treatment! https://www.prnewswire.com/news-releases/viriom-initiates-phase-1-clinical-trial-of-once-monthly-injectable-hiv-treatment-300769370.html

11/15/2018

Happy to Welcome Snap Bio into our i2020 Accelerator investment framework and Excited to Help Advance their Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases - https://www.prnewswire.com/news-releases/torrey-pines-investments-i2020-accelerator-to-advance-snap-bios-selective-kinase-inhibitor-platform-for-treatment-of-endodermal-cancers-and-autoimmune-diseases-300750928.html

06/04/2018

Excited about our new partnership with 19Labs, creator of telehealth solutions that make quality health care accessible and affordable anytime, anywhere through connected kiosks and tablets, smart diagnostic devices, an intelligent deployment platform and management system. https://lnkd.in/gJwm3CZ